APG Asset Management N.V. trimmed its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 48.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 68,894 shares of the company's stock after selling 64,301 shares during the quarter. APG Asset Management N.V.'s holdings in Teva Pharmaceutical Industries were worth $1,466,000 at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. Oarsman Capital Inc. bought a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter valued at approximately $29,000. Wilmington Savings Fund Society FSB purchased a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter worth about $50,000. Ameliora Wealth Management Ltd. purchased a new position in Teva Pharmaceutical Industries during the 4th quarter valued at about $66,000. IFP Advisors Inc boosted its stake in Teva Pharmaceutical Industries by 96.1% during the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock worth $88,000 after acquiring an additional 1,960 shares in the last quarter. Finally, Quadrant Capital Group LLC increased its stake in shares of Teva Pharmaceutical Industries by 27.7% during the fourth quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company's stock valued at $96,000 after purchasing an additional 949 shares in the last quarter. Institutional investors own 54.05% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research firms recently weighed in on TEVA. UBS Group reduced their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, January 30th. Barclays lowered their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Thursday, January 30th. Piper Sandler raised their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research note on Friday, January 17th. StockNews.com downgraded shares of Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research note on Monday. Finally, Bank of America reduced their price target on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research report on Thursday, March 6th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $23.43.
View Our Latest Report on Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Stock Performance
TEVA stock traded down $0.02 on Tuesday, hitting $13.59. The company had a trading volume of 7,201,630 shares, compared to its average volume of 9,894,315. The stock has a market cap of $15.40 billion, a price-to-earnings ratio of -9.37, a P/E/G ratio of 1.44 and a beta of 0.72. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The stock's 50-day simple moving average is $15.71 and its 200 day simple moving average is $17.79. Teva Pharmaceutical Industries Limited has a 12-month low of $12.47 and a 12-month high of $22.80.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, equities research analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.
About Teva Pharmaceutical Industries
(
Free Report)
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Further Reading
Before you consider Teva Pharmaceutical Industries, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.
While Teva Pharmaceutical Industries currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
